Swiss ADC Manufacturers: 2026 Industry Guide

Switzerland has quietly become one of the most concentrated geographies on earth for antibody-drug conjugate (ADC) development and manufacturing. Four sites, Lonza in Visp, Cerbios-Pharma in Lugano, ADC Therapeutics in Lausanne, and Araris Biotech near Zurich, now anchor a sector serving a global ADC market projected to grow from USD 13.63 billion in 2025 to USD 15.41 billion in 2026.

How Big Is the ADC Opportunity for Swiss Manufacturers?

The headline numbers explain why every major Swiss CDMO has poured capital into bioconjugation suites since 2023. The global antibody-drug conjugate market is projected to grow at an 11.04% CAGR between 2026 and 2034, according to Nova One Advisor, reaching USD 34.87 billion by 2034. The contract manufacturing segment is moving even faster. According to DCAT Value Chain Insights, the global ADC contract manufacturing market was valued at USD 1.79 billion in 2024 and is forecast to compound at 13% per year, reaching approximately USD 6.87 billion by 2035.

Within that contract manufacturing spend, the segments break down roughly as: antibody (40%), conjugation and linker (30%), HPAPI and cytotoxic payload (20%), and fill-finish (10%). That structure favors integrated providers who can offer the full ADC drug substance under one roof. Switzerland has more of those than any country except the United States.

For mid-sized Swiss CDMOs, specialty payload producers, and clinical-stage biotechs, the question is not whether demand exists. The question is whether their sales engine can put the right capability in front of the right pharma buying committee before a competitor in Singapore, North Carolina, or Belgium gets there first.

Who Are the Main Swiss ADC Manufacturers?

The Swiss ADC cluster is small in headcount but unusually deep in capability. Four sites do most of the work.

Lonza (Visp)

Lonza is the largest biologics CDMO in the world and the gravitational center of Swiss bioconjugation. The company is mid-way through a multi-year capacity build at its Visp site. According to Manufacturing Chemist, Lonza announced on November 12, 2024 two new multipurpose 1,200 L bioconjugation suites spanning around 2,000 square meters. The expansion is expected to be operational in 2028, will double Lonza’s commercial bioconjugate supply capacity, and will create approximately 200 new jobs in the Valais region. Additional drug product filling capacity is being layered in alongside.

That sits on top of an earlier customer-dedicated expansion at Ibex Dedicate Biopark in Visp, projected operational in 2026, plus a separate dedicated suite scheduled for 2027. Together, by the end of the decade, Visp will host one of the largest concentrations of commercial-scale bioconjugation capacity anywhere.

Cerbios-Pharma (Lugano)

Cerbios-Pharma is one of the few CDMOs globally able to offer a single entry point for the manufacturing of ADC drug substance plus all its components, mAbs, payloads, toxins, in a single site. According to Cerbios-Pharma, the company opened a new HPAPI and ADC payload manufacturing area at the Lugano site, with two cGMP manufacturing lines using isolator containment technology rated to occupational exposure limits below 10 ng/m³, single-use reactors up to 100 L, and batch scales from grams to kilograms. The facility holds Swissmedic approval. Cerbios has publicly stated its target to double ADC capacity through investment in a new hub.

In May 2025, Cerbios was acquired by HAS Healthcare Advanced Synthesis SA, backed by 65 equity partners, in a deal designed to build a top-tier global CDMO group.

ADC Therapeutics (Lausanne)

ADC Therapeutics is not a CDMO but a commercial-stage ADC company headquartered at the Biopôle life sciences campus in Lausanne. Its lead product ZYNLONTA (loncastuximab tesirine-lpyl) holds FDA accelerated approval and EC conditional approval for relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. The company has reported encouraging Phase 1b LOTIS-7 data in combination with the bispecific antibody glofitamab, with an 89.8% ORR and 77.6% CR across 49 efficacy-evaluable patients at six months follow-up, per the December 2025 update. The company is also advancing a PSMA-targeting next-generation ADC with an exatecan payload and proprietary hydrophilic linker.

Araris Biotech (Zurich region)

Araris Biotech is a spin-off from the Paul Scherrer Institute (PSI) and ETH Zurich, based in Au, near Zurich. Its AraLinQ peptide linker platform enables site-specific, one-step payload attachment to off-the-shelf antibodies without re-engineering. In March 2025, Taiho Pharmaceutical announced its acquisition of Araris for USD 400 million upfront plus up to USD 740 million in milestone payments. Araris continues to operate as a wholly owned subsidiary from Switzerland, with three preclinical ADC programs and partnerships including Johnson & Johnson and Chugai Pharmaceutical.

The Wider Cluster

The four anchors sit inside a broader ecosystem. Carbogen AMCIS raised CHF 25.5 million in June 2025 to outfit two of its three Swiss facilities for commercial linker manufacturing. Alentis Therapeutics is advancing a Claudin-1 ADC (ALE.C07) in early clinical testing after a USD 181.4 million Series D in November 2024. Companies in this orbit feed payload, linker, and analytical capabilities into the larger CDMO supply chains.

What Is the Swiss Competitive Advantage?

Three structural factors make Switzerland punch above its weight in ADC manufacturing.

Integrated supply at one site. Few geographies allow a sponsor to produce mAb, payload, and linker, run conjugation, and execute fill-finish under one quality system. Cerbios offers this in Lugano. Lonza offers a parallel integrated model in Visp. That collapses tech transfer cost, regulatory risk, and lead time.

Regulatory credibility. Swissmedic, EMA, and FDA inspections of Swiss sites carry weight with sponsors who need to file ADC drug master files across multiple jurisdictions. The reputation is decades old and hard to replicate.

Adjacent science. ETH Zurich, EPFL Lausanne, the Paul Scherrer Institute, and the University of Basel feed the talent pool. The Basel Area alone hosts around 800 life sciences companies and over 33,000 professionals, anchored by Roche and Novartis, making it one of Europe’s most significant biopharma clusters. That density is why most ADC startup spin-outs emerge here rather than relocating elsewhere.

Why Traditional Sales Channels Are Failing Swiss ADC Players

Capacity is only half the equation. Selling ADC services into a global pharma buying committee is structurally hard, and the channels Swiss manufacturers have historically relied on are getting more expensive and less effective.

World ADC London, CPHI Worldwide, BIO International, DCAT Week. These are the must-attend events for ADC business development. The 15th World ADC London 2025 drew over 1,000 attendees and 120 speakers; the 16th edition in 2026 hosted 800+ industry attendees from 240+ companies. CPHI Worldwide 2025 in Frankfurt attracted 2,400 exhibiting firms and 67,000 visitors. The booths, hospitality, travel, and staffing for a serious presence at all four major events runs into seven figures annually. Cost per qualified lead through trade fairs sits at $300 to $900+. You meet whoever passes your booth, mostly procurement-level contacts, rarely the CMC leads, quality directors, or regulatory heads who actually choose ADC partners.

Field business development reps. A pharma BD professional with ADC technical fluency, regulatory chops, and the language coverage to handle EU and North American accounts costs $150,000 to $250,000 annually loaded. To cover the major ADC sponsor hubs in Boston, San Francisco, the UK, Germany, and Japan, you need a team of five. Cost per qualified lead through field BD: $500 to $1,200+.

Scientific advisor and KOL networks. Traditional in pharma, but slow to scale. Each relationship covers a narrow modality or therapeutic area and depends on personal trust. You cannot KOL-network into 200 ADC sponsor accounts simultaneously.

Distributor and agency lock-in. Less common in CDMO services, but where it exists, it removes visibility into the actual sponsor pipeline and erodes pricing power.

Cold calling across borders. Effective when done by a senior native-language BD professional with technical credibility. Nearly impossible to staff across English, German, French, Japanese, and Mandarin simultaneously at the volume Swiss ADC players need.

Trade missions and S-GE delegations. Switzerland Global Enterprise runs a dedicated Swiss Pavilion at CPhI Worldwide and similar export promotion activities. Useful, but episodic. A delegation trip produces a handful of meetings, not a sustained pipeline.

The structural problem is the same across all of these channels: they reach one person at a time, when an ADC partnership decision typically involves five to eleven stakeholders, consistent with Gartner research on B2B buying groups.

What a Modern Pipeline Engine Looks Like for ADC CDMOs

The buyer side of ADC contracting has changed faster than the seller side. Sponsors run formal RFI/RFQ processes, score CDMOs on a defined criteria set, and shortlist from a global pool. To win a slot on those shortlists, Swiss manufacturers need to be visible to multiple stakeholders at every relevant sponsor before the RFI hits.

That is what an AI-powered outbound engine is built to do. Instead of one BD rep working one account at a time, the engine maps the global ADC sponsor universe, identifies every relevant buying-committee role at each target, and runs personalized multi-threaded outreach calibrated to each stakeholder’s responsibilities. The procurement contact sees capacity and pricing. The CMC lead sees process descriptions and analytical data. The quality director sees audit history and GMP certificates. The regulatory affairs lead sees DMF references and Swissmedic correspondence.

The engine also watches buying signals in real time: new IND filings, patent expirations on biologics, Phase 3 readouts, capacity announcements at competing CDMOs, leadership changes in procurement and supply chain. When a signal indicates a sponsor is moving from clinical to commercial supply, the outreach lands at the moment they are most open to a new partner.

The cost dynamics matter. Trade fairs scale linearly and field BD scales worse than linearly. An AI outbound engine starts at $150 to $300 per qualified lead depending on geography and sector, and gets cheaper the longer it runs because the data on what works compounds. The second 1,000 ADC sponsor prospects cost less to reach than the first 1,000. That is the structural advantage versus channels with a built-in ceiling.

For a closer look at how this works in practice for Swiss pharma and biotech more broadly, see our Swiss pharma export guide and Switzerland manufacturing exports overview. For the engine architecture itself, see How It Works.

Practical Starting Points

Swiss ADC manufacturers do not need to dismantle existing channels overnight. The migration is incremental:

1. Define your ICP precisely. Which sponsor stage (preclinical, Phase 1, Phase 3, commercial), which modality (mAb, payload, linker, conjugation, fill-finish), which therapeutic area, and which geographies represent your highest-value opportunities?
2. Map buying committees at the top 100 sponsor accounts. Procurement, CMC, quality, regulatory, supply chain, plus the program-level sponsors.
3. Organize your technical content for digital delivery. DMF references, GMP certificates, audit history, capability decks, capacity tables, stability data summaries, and case-study redactions.
4. Run a controlled multi-threaded pilot. Start with 50 to 100 sponsor accounts. Measure response rates by role and signal type.
5. Iterate based on what wins. The engine learns which combinations of role, message, and timing convert. Reallocate spend toward those combinations.

Frequently Asked Questions

Who are the largest ADC manufacturers in Switzerland?

The four anchor sites are Lonza in Visp (the world’s largest biologics CDMO and home to multiple ongoing bioconjugation suite expansions), Cerbios-Pharma in Lugano (integrated ADC drug substance manufacturing), ADC Therapeutics in Lausanne (commercial-stage ADC company), and Araris Biotech near Zurich (linker technology, acquired by Taiho Pharmaceutical in March 2025).

How fast is the ADC market growing?

The global ADC market is projected to grow from USD 13.63 billion in 2025 to USD 15.41 billion in 2026, according to Nova One Advisor, then to USD 34.87 billion by 2034 at an 11.04% CAGR. The ADC contract manufacturing segment specifically is forecast to grow at around 13% per year through 2035, per DCAT Value Chain Insights.

What capacity is Lonza adding for ADCs?

Lonza announced in November 2024 two new 1,200 L multipurpose bioconjugation suites in Visp, spanning around 2,000 square meters, expected operational in 2028 and creating approximately 200 jobs. This doubles Lonza’s commercial bioconjugate supply capacity. Additional customer-dedicated suites are scheduled for 2026 and 2027.

How do Swiss ADC manufacturers reach global pharma sponsors?

The traditional channels are World ADC London, CPHI Worldwide, BIO International, DCAT Week, scientific advisor networks, and field business development teams. These produce qualified leads at $300 to $1,200+ each and scale linearly. AI-powered outbound engines map sponsor buying committees, run multi-threaded personalized outreach, and watch real-time signals, typically at $150 to $300 per qualified lead with costs that decrease over time.

Is the Araris and Cerbios M&A activity a sign the sector is consolidating?

Yes. The Taiho acquisition of Araris (March 2025, up to USD 1.14 billion all-in) and the HAS Healthcare acquisition of Cerbios-Pharma (May 2025) both reflect strategic capital flowing into Swiss ADC capability. Sponsors and CDMO groups want secured access to bioconjugation capacity, linker IP, and integrated drug substance manufacturing. Expect more deals through 2026 and 2027 as global commercial capacity tightens.

---

Building global pipeline for a Swiss CDMO, payload specialist, or clinical-stage ADC company? Talk to papaverAI about how an AI-powered outbound engine fits alongside your existing BD team. Or explore our case studies to see how we built pipeline for other manufacturing clients.